Scribd
Upload
859 views13 pages

LATEST PPT - Wockhardt

Wockhardt is a pharmaceutical company headquartered in Mumbai, India with manufacturing plants in several countries including India, UK, Ireland, France and the US. It has subsidiaries in the US, UK, Ireland and France, and was founded in the 1960s. Wockhardt has expertise in recombinant biotechnology and a strong presence in the European market, though debt levels are high and integration of acquired businesses remains a challenge. Key products and therapies include insulin, diabetes drugs, pain treatments, and neuropsychiatry medications.

Uploaded by

Naman Maharaja
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPT, PDF, TXT or read online on Scribd
859 views13 pages

LATEST PPT - Wockhardt

Wockhardt is a pharmaceutical company headquartered in Mumbai, India with manufacturing plants in several countries including India, UK, Ireland, France and the US. It has subsidiaries in the US, UK, Ireland and France, and was founded in the 1960s. Wockhardt has expertise in recombinant biotechnology and a strong presence in the European market, though debt levels are high and integration of acquired businesses remains a challenge. Key products and therapies include insulin, diabetes drugs, pain treatments, and neuropsychiatry medications.

Uploaded by

Naman Maharaja
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPT, PDF, TXT or read online on Scribd
You are on page 1/ 13

INTRODUCTION

A pharmaceutical and biotechnology


company headquartered in Mumbai, India.

- Manufacturing plants in India, UK, Ireland, France and US.

-Subsidiaries in US, UK, Ireland and France.

-Founded by Habil Khorakiwala in the early 1960s.

- First company outside of the US and Europe to manufacture


recombinant human insulin.
SWOT ANALYSIS

STRENGTHS

• Strong expertise in the area of Recombinant


Biotechnology
• Strong presence in the European market (50%+
revenue comes from Europe)
• Significant ramping up of the US business (with a
growth of 50%)
• Robust manufacturing infrastructure
• Strong insulin portfolio in India
WEAKNESSES

• Less contribution towards revenues by the US


business

• High debt burden


OPPORTUNITIES
• Leverage on synergies present in the European
market

• Launch of Glaritus
THREATS

• Integration of European businesses is a major challenge (Negma


and Pinewood acquisitions have to be integrated with the UK
business)
• Pricing pressure in the US may restrict expected revenue
growth (price erosion more than 95%) specially in cephalosporin
segment, with growing competition from companies like Orchid
Chemicals and Lupin
• High competition for EPO in regulated markets
• Increasing competition in the European generic market with the
growing presence of frontline Indian pharma companies including
Ranbaxy and Reddys
MARKET

• Annual turnover of US$ 650 million, and a market capitalisation


of over $ 1 billion.

• Wockhardt has revenue of Rs 4,501 crore and operating profit


(EBIDTA) at Rs 823 crore during the 15 months period (Jan
2009 – Mar 2010).

• For the quarter (Jan-March 2010) , the sales revenue was Rs 872
crore and operating profit (EBITDA) was Rs 158 crore.
GROWTH

• India Business:
Wockhardt’s India branded business grew by 24% in Jan-Mar
2010 over the corresponding period of 2009.
• Europe Business:
Wockhardt UK grew by 19% compared to the industry growth
of only 5% in Jan-Mar 2010 over the corresponding period of
2009.
• USA Business:
Wockhardt`s Morton Grove Pharmaceuticals business has
shown a robust 40% growth in Jan-Mar 2010 over the
corresponding period of 2009.
TOP PRODUCTS

DIABETOLOGY NEPHROLOGY
Wosulin (Recombinant Insulin ) Wepox (Recombinant
Mopaday (Oral Antidiabetic) Erythropoietin)
Glimaday (Oral Antidiabetic)

PAIN MANAGEMENT: NUTRITION


Proxyvon Methycobal
Dexolac
NEURO-PSYCHIATRY
Spasmo-Proxyvon

NEURO-PSYCHIATRY COUGH THERAPY


Libotryp Zedex
Tryptomer Bro-Zedex
Viscodyne
PRODUCT-WISE VALUES

PRODUCTS Value in Crores % +/- %

Spasmo-Proxyvon 89.41 0.21 7.4

Dexolac 61.99 0.14 26.9

Bro-Zedex 30.38 0.07 36.9

Magenta 30.31 0.07 -1.9

Zedex 28.27 0.07 41

Proxyvon 24.2 0.06 21.4

Merideca 23.5 0.05 -17.5

Wokadine 23.47 0.05 36.8


NEW LAUNCHES

• Insulin Glaritus
• Tamsulosin capsules(Flomax)
• Amoxicillin Clav K OS,
• Azithromycin Tablets,
• Divalproex Extended Release Tablets
• Midazolam HCI Injection,
• Nicardipine Injection,
• Ranitidine Tablets,
• Risperidone Tablets,
• Ropinirole HCI Tablets
TOP COMPETITORS

• Aurobindo Pharma Limited


• Cipla Limited
• Glaxo Smithkline Pharmaceuticals Limited
• Dr. Reddy's Laboratories Limited
• Ranbaxy Laboratories Limited

You might also like